ArticleBlood cancer journal2026

Peri-transplant TP53 molecular MRD as a prognostic biomarker of relapse in TP53-mutated AML/MDS undergoing allogeneic HCT.

Yeqian Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.